CHEMEDIUM SIGNALFINANCIAL10-K

CHE significantly reduced debt and cash positions while maintaining aggressive share buyback activity, suggesting active capital structure optimization despite declining profitability.

The company appears to be executing a deliberate deleveraging strategy, reducing debt by 47% while simultaneously returning substantial capital to shareholders through increased buybacks. However, the 12% decline in net income combined with reduced cash reserves (down 58%) may indicate earnings pressure or reduced financial flexibility for future growth investments.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

CHE's financial profile shows a mixed picture of capital allocation priorities and operational challenges. While the company strengthened its balance sheet by reducing debt by $87.5M and maintained aggressive shareholder returns through $431.5M in buybacks, core profitability declined 12% to $265.2M and cash reserves dropped dramatically from $178.3M to $74.5M. The combination of reduced liquidity, higher capital expenditures, and lower earnings suggests the company may be prioritizing debt reduction and shareholder returns over maintaining financial flexibility, which could limit its ability to respond to growth opportunities or operational challenges.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-58.2%
$178.3M→$74.5M

Cash declined 58.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
-47.3%
$185.0M→$97.5M

Debt reduced 47.3% — deleveraging strengthens balance sheet and reduces financial risk.

Capital Expenditure
Cash Flow
+26.8%
$49.5M→$62.8M

Capex increased 26.8% — ongoing investment in capacity or infrastructure for future growth.

Current Assets
Balance Sheet
-23.3%
$394.7M→$302.6M

Current assets declined 23.3% — monitor working capital adequacy and short-term liquidity.

Share Buybacks
Cash Flow
+19.4%
$361.4M→$431.5M

Share repurchases increased 19.4% — management returning capital, signals confidence in intrinsic value.

Stockholders Equity
Balance Sheet
-12.5%
$1.1B→$979.4M

Equity decreased 12.5% — buybacks or losses reducing book value, monitor solvency ratios.

Net Income
P&L
-12.2%
$302.0M→$265.2M

Net income declined 12.2% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
On February 10, 2026, 13,765,136 shares of Chemed Capital Stock (par value $1 per share) were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 28 Item.7A.
Approximately 20% of all hospice providers are not-for-profit.
Roto-Rooter s ability to engage in the plumbing repair, excavation and water restoration businesses is also subject to certain limitations and restrictions imposed by state and local licensing laws and regulations.
In the event that these Certificate of Need laws and similar restrictions are removed or their impact is weakened in any geography in which VITAS already operates, additional competitors may be able to enter those markets more easily, and potentially adversely affect VITAS.
Additionally, if any state or federal agency places a moratorium on new hospices or hospice expansion in any geography, it could adversely affect VITAS growth potential.
Increases in operating costs, such as labor, pharmaceutical and supply costs that are subject to inflation and other increases related to tariffs or other tax increases, without a compensating increase in Medicare and Medicaid rates, could have a material adverse effect on VITAS business in the future.
6 These caps apply to hospices programs by billing number; Accordingly, for larger programs, the effect of a cap limitation can be sizable and adversely affect revenue.
Reimbursement from state Medicaid programs in 2025 accounted for approximately 3% of VITAS revenues.
On July 31, 2025, the Centers for Medicare and Medicaid Services released the 2026 inflationary increase effective October 1, 2025, which was 2.6%.
REMOVED
On February 10, 2025, 14,636,695 shares of Chemed Capital Stock (par value $1 per share) were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 26 Item.7A.
Approximately one quarter of all hospice providers are not-for-profit.
In the event that these restrictions are removed or their impact is lessened in any geography in which VITAS already operates, additional competitors may more easily be able to enter those markets, and potentially adversely affect VITAS.
Reimbursement from state Medicaid programs in 2024 accounted for approximately 4% of VITAS revenues.
On September 11, 2024, the Centers for Medicare and Medicaid Services released the 2025 inflationary increase effective October 1, 2024, which was 2.9%.
Currently, VITAS is one of a group of hospice providers selected by the OIG s Office of Audit Services ( OAS ) for inclusion in an audit of the provision of elevated level-of-care hospice services to a sample of patients.
Please see Note 18 Legal and Regulatory Matters for a further description of the audit and claims that have risen from the audit.
Of this balance, $895,000 is included in other liabilities and $826,000 is included in other current liabilities.
Although regulations for these laws have not yet been finalized, these statutes will require the Company to report on its greenhouse gas emissions and report its climate-related financial risk, as well as efforts taken to mitigate that risk, beginning as early as 2026.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →